Esophageal cancer in Hispanic patients: A demographic analysis of the National Cancer Database.

Authors

null

Juan Ricardo

Florida State University College of Medicine, Sarasota, FL

Juan Ricardo , Jorge Conte , Talal Alkayali , Ahmed Salem , Jamie Huston , Ravi Shridhar , Kenneth L Meredith

Organizations

Florida State University College of Medicine, Sarasota, FL, Sarasota Memorial Hospital, Sarasota, FL, University of Central Florida, Orlando, FL

Research Funding

Other

Background: Hispanics are the fastest-growing minority accounting for 18% of the US population. The National Cancer Institute estimated 17,290 new cases of esophageal cancer (EC) in the US in 2018. Hispanics are reported to have lower EC prevalence. We sought to interrogate the demographic patterns of EC in Hispanics. Secondary objective was to examine evidence of socioeconomic disparities and differential therapy. Methods: We queried the National Cancer Database to identify patients with EC between 2005–2015. Patients were divided into two groups, Hispanic vs Non-Hispanic (NH). Demographics compared were age, sex, tumor data, surgical intervention, type of treatment, insurance status, income, residence area, and Charlson/Deyo score. Pearson’s Chi-square test was used to compare categorical variables. Groups were matched by propensity score-matched analysis (PSM). Survival analysis was estimated by the Kaplan-Meier method and associated log-rank test. P-value ≤0.05 was considered significant. Results: We identified 85,004 patients with EC; 3,205 were Hispanic (3.8%). In this US population we identified significant disparities between the Hispanic and NH groups. Statistically significant differences among Hispanics included higher prevalence of squamous EC (24.7% vs 19.6%), higher likelihood of stage IV cancer diagnosis (40.7% vs. 34.8%), younger age, higher uninsured status (10.4% vs 3%) with income < $38,000 (26.4% vs 15.9%), and Charlson/Deyo score 0 (72.3% vs 70.7%) when compared to NH. However, Hispanics were less likely to have surgical intervention (29% vs 36.3) and overall less likely to receive any type of treatment (30.1% vs 26.1%). PSM showed that any treatment, insurance status and lower income were predictors of survival. Treated Hispanics survived longer than NH (median survival 17 vs 15 months). Overall survival at 5 years was 22% vs 17%, respectively, p < 0.05. Conclusions: Despite lower prevalence of EC in Hispanics compared to NH, there is a disproportionately higher number of metastatic and untreated cases among Hispanics. This disparity may be explained by Hispanics' limited access to medical care exacerbated by their socioeconomic and insurance status. Further clinical and epidemiologic research is warranted to reveal other factors impacting these health disparities.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research, Clinical Informatics, and Quality of Care

Track

Quality Care/Health Services Research

Sub Track

Access to Care

Citation

J Clin Oncol 37, 2019 (suppl; abstr 6561)

DOI

10.1200/JCO.2019.37.15_suppl.6561

Abstract #

6561

Poster Bd #

252

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Esophageal cancer in Hispanics: A propensity score matched analysis of the National Cancer Database.

First Author: Kenneth Lee Meredith

Abstract

2023 ASCO Quality Care Symposium

Access to radiotherapy in Hispanic and Latinx populations in the United States: An update.

First Author: Nicholas Peter Verdini